Earnings Ahead

BMRN - BioMarin Pharmaceutical Inc.

76.22 -3.37 -4.23

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

About

Profile

BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare diseases driven by genetic causes At BioMarin, we focus on developing first-in-class and best-in-class therapeutics that provide meaningful advances to


Headquarters

Novato, California, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

BMRN



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.46 misses by $0.02, revenue of $581.3M misses by $26.46M
  • BioMarin appoints Alexander Hardy as president and chief executive officer
  • BioMarin Pharmaceutical Q3 2023 Earnings Preview
  • Bernstein upgrades BioMarin to market perform, citing valuation
  • FDA approves use of BioMarin drug Voxzogo in children under 5
  • BioMarin a market perform at Raymond James due to growth concerns
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.54 beats by $0.07, revenue of $595.3M in-line
  • BioMarin Pharmaceutical Q2 2023 Earnings Preview
  • BioMarin upgraded at BMO after FDA nod for hemophilia A therapy
  • BioMarin granted FDA nod for hemophilia A gene therapy
  • Eli Lilly, Humana among best health care names in defensive environment - BofA
  • BioMarin Pharmaceutical Non-GAAP EPS of $0.60 beats by $0.20, revenue of $596.4M beats by $26.01M
  • BioMarin Pharmaceutical Q1 2023 Earnings Preview
  • What is behind biotech M&A resurgence?
  • FDA to back accelerated approval pathway for gene therapies
  • BioMarin seeks FDA nod to expand use of its Voxzogo treatment in children under five
  • BioMarin's Roctavian gets FDA action date extended to end of June
  • BridgeBio soars 55% after Phase 2 data for achondroplasia candidate
  • BioMarin Pharmaceutical GAAP EPS of $0.00 beats by $0.07, revenue of $537.5M misses by $0.74M
  • BioMarin Pharmaceutical Q4 2022 Earnings Preview
Date Price Open High Low Vol Change
Dec 4 53.85 54.33
54.66
53.64
1.4M -0.85%
Dec 3 54.31 53.52
54.4
53.03
2.2M 0.78%
Dec 2 53.89 55.22
55.34
53.88
2.1M -2.07%
Dec 1 55.03 55.5
56.09
54.95
2.3M -1.61%
Nov 28 55.93 55.77
56.05
55.03
1.2M 0.74%
 
Nov 26 55.52 56.26
56.39
54.51
3.6M -1.37%
Nov 25 56.29 55.6
56.45
55.35
2.5M 1.42%
Nov 24 55.5 54.22
56.13
53.93
17.4M 1.48%
Nov 21 54.69 52.72
54.76
52.51
3.0M 4.21%
Nov 20 52.48 52.62
53.72
52.36
2.1M -0.15%
Nov 19 52.56 53.88
53.88
51.99
2.1M -2.95%
Nov 18 54.16 54.32
54.52
52.91
2.0M -0.55%
Nov 17 54.46 54.13
55.24
54
2.2M -0.49%
Nov 14 54.73 54.18
55.29
53.67
2.0M 0.94%
Nov 13 54.22 55
55.34
54.16
2.3M -1.99%
Nov 12 55.32 54.94
55.33
54.31
2.1M 0.71%
Nov 11 54.93 53
54.97
52.85
2.3M 4.29%
Nov 10 52.67 51.94
52.8
51.81
2.1M 2.35%
Nov 7 51.46 51.9
51.9
50.76
3.1M -0.73%
Nov 6 51.84 52.03
52.68
51.42
3.0M -1.82%
Nov 5 52.8 52.17
53.5
51.86
2.1M 0.53%
Nov 4 52.52 52.56
52.76
51.8
2.0M -0.62%
Nov 3 52.85 53.03
54.25
52.06
2.7M -1.34%
Oct 31 53.57 51.33
53.62
51
3.3M 3.20%
Oct 30 51.91 51.86
52.49
51.1
2.7M 0.10%
Oct 29 51.86 53.46
54.75
51.74
4.8M -3.05%
Oct 28 53.49 53.4
56.8
53.27
6.5M 1.56%
Oct 27 52.67 54.98
55.84
52.26
5.5M -3.32%
Oct 24 54.48 54.49
55.03
54.19
2.1M -0.13%
Oct 23 54.55 53.49
54.61
53.14
2.3M 2.21%
Oct 22 53.37 53.81
54.41
53.22
2.5M -0.82%
Oct 21 53.81 53.08
53.98
52.62
1.9M 1.39%
Oct 20 53.07 53.54
53.54
52.14
2.0M -0.41%
Oct 17 53.29 52.6
53.49
52.58
1.8M 0.64%
Oct 16 52.95 53.09
53.96
52.38
2.2M -0.26%
Oct 15 53.09 52.34
53.76
52.19
1.9M 1.18%
Oct 14 52.47 51.78
52.81
51.56
2.5M 0.04%
Oct 13 52.45 52.58
52.9
51.85
2.3M 0.25%
Oct 10 52.32 54.16
54.25
51.78
3.0M -2.84%
Oct 9 53.85 55.39
55.39
53.74
3.4M -1.54%
Oct 8 54.69 54.57
55.2
54.18
1.3M -0.02%
Oct 7 54.7 55.92
56.26
54.58
1.6M -1.64%
Oct 6 55.61 56.06
56.06
55.28
1.8M 0.32%
Oct 3 55.43 55.5
56
55.01
2.4M -0.25%
Oct 2 55.57 54.9
55.99
54.58
2.1M 1.29%
Oct 1 54.86 54.29
55.75
54.26
2.9M 1.29%
Sep 30 54.16 53.96
54.42
53.19
1.8M 0.26%
Sep 29 54.02 53.76
54.38
53.5
1.6M 0.32%
Sep 26 53.85 53
53.97
52.65
1.8M 2.34%
Sep 25 52.62 54.18
54.5
52.47
2.7M -2.14%
Sep 24 53.77 53.2
53.87
53
1.4M 0.67%
Sep 23 53.41 54.09
54.12
52.91
2.0M -0.98%
Sep 22 53.94 54.35
54.7
53.81
2.0M -0.77%
Sep 19 54.36 55.52
55.52
54.21
5.0M -1.41%
Sep 18 55.14 54.57
55.22
54.43
1.5M 1.42%
Sep 17 54.37 53.85
55.18
53.62
2.7M 0.80%
Sep 16 53.94 53.2
54.42
53.15
2.3M 1.51%
Sep 15 53.14 54.25
54.39
52.94
1.8M -1.76%
Sep 12 54.09 55.65
56.07
54.05
1.9M -3.26%
Sep 11 55.91 54.46
55.94
54.2
2.0M 0%